StockData
BioNTech SE logo

BioNTech SE (BNTX) stock

BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026Score 3/30
$88.17−0.96 (-1.08%)

Close on Oct 30, 2026Market cap $22.15BP/E –Yield –

Earnings

BioNTech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2025
€907.40M
-23.7% on a year earlier
Adjusted diluted loss per share, Q4 FY2025
-0.33 EUR
1.08 EUR a year earlier
Latest guidance
Raised
Mar 10, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of BioNTech's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open€907.40M-23.7%-1.25 EUR-0.33 EURRelease
Q4 FY2024ended Dec 31, 2024Mar 10, 2025before the open€1.19B-19.5%1.08 EUR–Release
Q4 FY2023ended Dec 31, 2023Mar 20, 2024before the open€1.48B–1.90 EUR–Release
Q4 FY2022ended Dec 31, 2022Mar 27, 2023before the open––––Release
Q4 FY2021ended Dec 31, 2021Mar 30, 2022before the open––––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

BioNTech's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenuesFY20251700 – 2200–NewMar 10, 2025
Capital expenditures for operating activitiesFY2025250 – 350–NewMar 10, 2025
R&D expensesFY20252600 – 2800–NewMar 10, 2025
SG&A expensesFY2025650 – 750–LoweredMar 10, 2025
total revenuesFY20262 – 2.3–NewMar 10, 2026
adjusted R&D expensesnon-GAAPFY20262.2 – 2.5–NewMar 10, 2026
adjusted SG&A expensesnon-GAAPFY2026700 – 800–RaisedMar 10, 2026

Guidance history

Every forecast BioNTech put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 10, 2026adjusted R&D expensesFY20262.2 – 2.5New
Mar 10, 2026adjusted SG&A expensesFY2026700 – 800Raised
Mar 10, 2026total revenuesFY20262 – 2.3New
Mar 10, 2025Capital expenditures for operating activitiesFY2025250 – 350New
Mar 10, 2025R&D expensesFY20252600 – 2800New
Mar 10, 2025SG&A expensesFY2025650 – 750Lowered
Mar 10, 2025revenuesFY20251700 – 2200New
Mar 20, 2024Capital expenditures for operating activitiesFY2024400 – 500New
Mar 20, 2024R&D expensesFY20242.4 – 2.6New
Mar 20, 2024SG&A expensesFY2024700 – 800Raised
Mar 20, 2024group revenueFY20242.5 – 3.1New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases BioNTech filed with the SEC as exhibits to Form 8-K or 6-K

  1. BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
    6-K
  2. BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
    6-K
  3. BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
    6-K
  4. BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
    6-K
  5. BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
    6-K
  6. 6-K exhibit EX-99.1
    6-K
  7. BioNTech Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer
    6-K
  8. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
    6-K
  9. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum
    6-K
  10. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
    6-K
  11. BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
    6-K
  12. Second Quarter 2026 Financial Results & Corporate Update August 4, 2026 Exhibit 99.1
    6-K
  13. BioNTech Announces Appointment of Guido Oelkers to
    6-K
  14. European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
    6-K
  15. Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of the Regulation (EU) No. 596/2014 and Art. 2(1) of the Delegated Regulation (EU) 2016/1052
    6-K